Zobrazeno 1 - 10
of 198
pro vyhledávání: '"Kent W Mouw"'
Autor:
Dag Rune Stormoen, Signe Lehn, Kent W. Mouw, Zoltan Szallasi, Linea Cecilie Melchior, Line Hammer Dohn, Judit Börcsok, Maria Rossing, Birgitte Grønkaer Toft, Helle Pappot
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Background Metastatic urothelial carcinoma (mUC) has a poor prognosis, despite recent therapeutic advancements. Prostaglandin Reductase 1 (PTGR1) is essential for activating acylfulvens, a promising class of drugs for treating a subset of ur
Externí odkaz:
https://doaj.org/article/cbe03a455d9d4cd08c3d82aaa8d9d930
Autor:
Aurel Prosz, Haohui Duan, Viktoria Tisza, Pranshu Sahgal, Sabine Topka, Gregory T. Klus, Judit Börcsök, Zsofia Sztupinszki, Timothy Hanlon, Miklos Diossy, Laura Vizkeleti, Dag Rune Stormoen, Istvan Csabai, Helle Pappot, Joseph Vijai, Kenneth Offit, Thomas Ried, Nilay Sethi, Kent W. Mouw, Sandor Spisak, Shailja Pathania, Zoltan Szallasi
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Due to a demonstrated lack of DNA repair deficiencies, clear cell renal cell carcinoma (ccRCC) has not benefitted from targeted synthetic lethality-based therapies. We investigated whether nucleotide excision repair (NER) deficiency is prese
Externí odkaz:
https://doaj.org/article/939969bbc4324201be410156a45cd9e5
Autor:
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D. Choudhury, Kent W. Mouw, Zoltan Szallasi, Lee Zou, Adam S. Kibel, Li Jia
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-19 (2023)
Identifying prostate cancer patients who may respond well to PARP inhibitors is important for their success in the clinic. Here, using a genome-wide CRISPR-Cas9 knockout screen, the authors identify MMS22L as a biomarker for sensitivity to PARP inhib
Externí odkaz:
https://doaj.org/article/ae5f553e58e5416b821643fde0923364
Autor:
Kasia M. Dillon, Raie T. Bekele, Zsofia Sztupinszki, Timothy Hanlon, Shahrzad Rafiei, Zoltan Szallasi, Atish D. Choudhury, Kent W. Mouw
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-6 (2022)
Abstract PARP inhibitors were recently approved for treatment of molecularly-defined subsets of metastatic castrate-resistant prostate cancer (mCRPC) patients. Although the PARP inhibitor olaparib was approved for use in patients with a mutation in o
Externí odkaz:
https://doaj.org/article/e1053094a65e49b4bf91021177e964ef
Autor:
Jonathan E. Leeman, MD, Daniel N. Cagney, MD, Raymond H. Mak, MD, Mai Anh Huynh, MD, PhD, Shyam K. Tanguturi, MD, Lisa Singer, MD, PhD, Paul Catalano, ScD, Neil E. Martin, MD, MPH, Anthony V. D'Amico, MD, PhD, Kent W. Mouw, MD, PhD, Paul L. Nguyen, MD, Martin T. King, MD, PhD, Zhaohui Han, PhD, Christopher Williams, PhD, Elizabeth Huynh, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 7, Iss 5, Pp 100934- (2022)
Purpose: Stereotactic magnetic resonance (MR)–guided adaptive radiation therapy (SMART) for prostate cancer allows for MR-based contouring, real-time MR motion management, and daily plan adaptation. The clinical and dosimetric benefits associated w
Externí odkaz:
https://doaj.org/article/ee672291acc44cc299d54b5b5e3760c9
Autor:
Justin Hwang, Xiaolei Shi, Andrew Elliott, Taylor E. Arnoff, Julie McGrath, Joanne Xiu, Phillip Walker, Hannah E. Bergom, Abderrahman Day, Shihab Ahmed, Sydney Tape, Allison Makovec, Atef Ali, Rami M. Shaker, Eamon Toye, Rachel Passow, John R. Lozada, Jinhua Wang, Emil Lou, Kent W. Mouw, Benedito A. Carneiro, Elisabeth I. Heath, Rana R. McKay, W. Michael Korn, Chadi Nabhan, Charles J. Ryan, Emmanuel S. Antonarakis
Publikováno v:
Clinical Cancer Research. :OF1-OF12
Purpose: In patients with metastatic prostate cancer (mPC), ATM and BRCA2 mutations dictate differences in PARPi inhibitor response and other therapies. We interrogated the molecular features of ATM- and BRCA2-mutated mPC to explain the divergent cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d167d2d8a4d064f76b84d6fc7c1b06cd
https://doi.org/10.1158/1078-0432.ccr-22-3394
https://doi.org/10.1158/1078-0432.ccr-22-3394
Autor:
Matthew Mossanen, Amin H. Nassar, Samantha M. Stokes, Nieves Martinez-Chanza, Vivek Kumar, Pier Vitale Nuzzo, David J. Kwiatkowski, Judy E. Garber, Catherine Curran, Dory Freeman, Mark Preston, Kent W. Mouw, Adam Kibel, Toni K. Choueiri, Guru Sonpavde, Huma Q. Rana
Publikováno v:
Clinical Genitourinary Cancer. 20:568-574
The familial aggregation of bladder cancers has been observed, but the incidence and association of familial bladder cancer with germline pathogenic and likely pathogenic (P/LP) variants is unknown.A retrospective analysis was conducted of patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48f7da4f9d3c9a382e084a6de841a6ca
https://doi.org/10.1016/j.clgc.2022.08.009
https://doi.org/10.1016/j.clgc.2022.08.009
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Externí odkaz:
https://doaj.org/article/d901046afb3941cbbf1185bb03fc3e57
Autor:
Kent W. Mouw, MD PhD, Beow Y. Yeap, ScD, Paul Caruso, MD, Aaron Fay, MD, Madhusmita Misra, MD MPH, Roshan V. Sethi, MD, Shannon M. MacDonald, MD, Yen-Lin Chen, MD, Nancy J. Tarbell, MD, Torunn I. Yock, MD MCH, Suzanne K. Freitag, MD, John E. Munzenrider, MD, Eric Grabowski, MD ScD, Michelle Katz, MD MPH, Karen Kuhlthau, PhD, Dawn DeCastro, MD, Gena Heidary, MD, Jessica Ciralsky, MD, Shizuo Mukai, MD, Helen A. Shih, MD
Publikováno v:
Advances in Radiation Oncology, Vol 2, Iss 1, Pp 44-52 (2017)
Purpose: Proton radiation therapy (PRT) is used to treat patients with retinoblastoma (RB) and has the potential to minimize exposure of normal tissue to radiation and thus decrease the risk of toxicity and second malignancies. However, comprehensive
Externí odkaz:
https://doaj.org/article/9b146fe9f60745a18dbb75148deb14f6
Autor:
Emmanuel S. Antonarakis, Charles J. Ryan, Chadi Nabhan, W. Michael Korn, Rana R. McKay, Elisabeth I. Heath, Benedito A. Carneiro, Kent W. Mouw, Emil Lou, Jinhua Wang, John R. Lozada, Rachel Passow, Eamon Toye, Rami M. Shaker, Atef Ali, Allison Makovec, Sydney Tape, Shihab Ahmed, Abderrahman Day, Hannah E. Bergom, Phillip Walker, Joanne Xiu, Julie McGrath, Taylor E. Arnoff, Andrew Elliott, Xiaolei Shi, Justin Hwang
Tumor mutation burden (muts/Mb) of ATM and BRCA2 mutant mPCs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::191c373d6a50da609d3a46c138118bcf
https://doi.org/10.1158/1078-0432.23223082.v1
https://doi.org/10.1158/1078-0432.23223082.v1
